Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

Based on 368 first isolates · MED-B · Cystitis (lower UTI) · 2025-09-28 → 2026-09-27
Internal medicine B
Per-organism detail: MED-B urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
nitrofurantoin 82 % (78 %–86 %)
No tissue or blood levels: cystitis only.
Not covered: Proteus mirabilis (7 %), Pseudomonas aeruginosa (5 %), Klebsiella pneumoniae (4 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
meropenem MEM
trend · Escherichia coli reserve
88 %
84 %
n = 37
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
83 %
81 %
n = 37
nitrofurantoin NIT
trend · Escherichia coli lower UTI only
82 %
84 %
n = 37
mecillinam MEC
trend · Escherichia coli lower UTI only
80 %
76 %
n = 37
ceftriaxone CRO
trend · Escherichia coli
79 %
73 %
n = 37
ciprofloxacin CIP
trend · Escherichia coli
77 %
70 %
n = 37
73 %
68 %
n = 37
trimethoprim TMP
trend · Escherichia coli lower UTI only
70 %
62 %
n = 37
45 %
57 %
n = 37
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
11 %
16 %
n = 37
5 %
5 %
n = 37
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
2 %
3 %
n = 37

Most likely organisms for this profile

Escherichia coli
59 %
Klebsiella pneumoniae
9 %
Enterococcus faecalis
8 %
Proteus mirabilis
7 %
Pseudomonas aeruginosa
5 %
Citrobacter freundii
5 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.